Clinical and polygraphic effects of d.1 5 HTP on narcolepsy-cataplexy

d.1 5 hydroxy-trytophan (600 mg a day) or a placebo were administered during 4 weeks following a double blind cross over design to 11 narcoleptic-cataplectic patients. Daily number of cataplectic and narcoleptic attacks did not vary. The 36 hours polygraphic recordings performed at the end of each treatment exhibit: a trend toward a decrease of the duration of the day time sleep and a significant increase of the duration of the night sleep.